& Rotter LLP, a Leading Securities Fraud Law FirmLOS ANGELES--([BUSINESS WIRE])--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Pinterest. Inc. ("Pinterest†or the "Company†) (NYSE: PINS) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PINTEREST, INC. (PINS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER ...

New York, New York--(Newsfile Corp. - February 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

Core Viewpoint - Inovio Pharmaceuticals, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its CELLECTRA device and its impact on FDA filing timelines [1] Group 1: Lawsuit Details - The class action lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is from October 10, 2023, to December 26, 2025, with a deadline for participation set for April 7, 2026 [1] - Allegations include that Inovio's public statements were materially misleading due to manufacturing deficiencies that could delay the filing of a Biologics License Application (BLA) with the FDA [1] Group 2: Company Impact - The lawsuit claims that Inovio did not gather necessary evidence to support a priority review by the FDA, further compounding the misleading nature of its public statements [1] - Shareholders who purchased shares during the class period and suffered losses are encouraged to contact the DJS Law Group for potential recovery [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The deadline to move the Court to serve as lead plaintiff is April 7, 2026, with the lead plaintiff acting on behalf of other class members [2] Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3] Group 3: Case Background - Inovio Pharmaceuticals is a biotechnology company focused on DNA medicines for diseases like human papillomavirus (HPV) [4] - The lawsuit alleges that Inovio made false or misleading statements regarding the manufacturing of its CELLECTRA device and the prospects of its INO-3107 Biologics License Application (BLA) to the FDA [4] - It is claimed that the company overstated the regulatory and commercial prospects of INO-3107, leading to investor damages when the true information became public [4]

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming April 7, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Inovio Pharmaceuticals, Inc. ("Inovio†or the "Company†) (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN INOVIO PHARMACEUTICALS, INC. (INO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PA. ...

Class Action Filed Against Inovio Pharmaceuticals, Inc. (INO) - April 7, 2026 Deadline to Join - Contact The Gross Law Firm [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO).Shareholders who purchased shares of INO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not require ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Inovio between October 10, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Faruqi ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the upcoming lead plaintiff deadline on April 7, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by April 7, 2026 [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field [4]. Group 3: Case Background - Inovio Pharmaceuticals is described as a biotechnology company focused on DNA medicines for diseases like human papillomavirus (HPV) [5]. - The lawsuit alleges that Inovio made false or misleading statements regarding the manufacturing of its CELLECTRA device and the prospects of its INO-3107 Biologics License Application (BLA) to the FDA, which were overstated [5].

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO). Shareholders who purchased shares of INO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/inovio-pharmaceuticals-inc-loss-submission-form-2/?id=183596&from=3 CLA ...

LOS ANGELES--(BUSINESS WIRE)---- $STOCKS--Law Offices of Frank R. Cruz Encourages Inovio Pharmaceuticals, Inc. (INO) Shareholders To Inquire About Securities Fraud Class Action. ...